Results 11 to 20 of about 21,507 (209)

Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome

open access: yesTH Open, 2020
Lupus anticoagulant is a misnomer as it is commonly associated with thromboembolic events. In few cases, the name retains its literal meaning when it characterizes patients with a bleeding disorder.
Vittorio Pengo   +7 more
doaj   +1 more source

Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients. [PDF]

open access: yesPLoS ONE, 2016
The activated partial thromboplastin time (APTT) assay is a basic hemostatic assay based on the time it takes for clots to form in plasma samples after the addition of calcium chloride. It is used to screen for various coagulation disorders.
Takayoshi Tokutake   +10 more
doaj   +1 more source

The Lupus Anticoagulant

open access: yesExperimental Biology and Medicine, 1984
Lupus-like anticoagulant (LLAC) is the term used to identify an acquired inhibitor (1) of blood coagulation, first described by Conley and Hartmann in patients with systemic lupus erythematosus (SLE) (2). A circulating “lupus-like” anticoagulant has been detected in 5-10% of all SLE patients.
N, Perico, F, Pusineri, G, Remuzzi
openaire   +2 more sources

Transmission of lupus anticoagulant by allogeneic stem cell transplantation

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2014
Passive transmission of autoimmune diseases by allogeneic stem cell transplantation is rare and is ascribed to passive transfer of memory B-cells from donor to recipient. We hereby report a case of transmission of an asymptomatic lupus anticoagulant from
Mira Romany Massoud   +5 more
doaj   +1 more source

Loss of antiphospholipid antibody positivity post-thrombosis in SLE

open access: yesLupus Science and Medicine, 2020
Background/Purpose Loss of positivity of antiphospholipid antibodies has been observed in clinical practice post-thrombosis in patients with SLE with secondary antiphospholipid syndrome (APS). Our study defined the frequency of this loss and the duration
Muznay Khawaja
doaj   +1 more source

Drug-Induced Lupus with Leukocytoclastic Vasculitis Associated with Apixaban

open access: yesCase Reports in Rheumatology, 2021
Drug-induced lupus is an iatrogenic-induced autoimmune disease with common offending agents well documented in the literature. To our knowledge, there are no prior case reports of drug-induced lupus associated with apixaban or any other direct oral ...
John Yang   +3 more
doaj   +1 more source

Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene

open access: yesThrombosis Journal, 2006
Background Lupus anticoagulants prolong clotting times in phospholipid-dependent coagulation tests. Lupus Ratio assays are integrated tests for lupus anticoagulants that may be based on APTT, RVVT or dPT clotting times. If a patient is being treated with
Wisløff Finn   +3 more
doaj   +1 more source

Osteomyelitis and septic arthritis in neonatal lupus erythematosus patients

open access: yesJournal of Pediatric Surgery Case Reports, 2022
Osteomyelitis in neonates is quite uncommon and often appears without a typical sign. Clinicians' late diagnosis and inappropriate treatment may result in severe sequelae. We report a rare case of osteomyelitis and septic arthritis infant with a mother's
Virany Diana   +4 more
doaj   +1 more source

Echocardiographic Abnormalities and Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus

open access: yesArquivos Brasileiros de Cardiologia, 2002
OBJECTIVE: Lupus anticoagulant and anticardiolipin antibodies (aCL) have been associated with thrombosis, recurrent abortion, and thrombocytopenia in patients with systemic lupus erythematosus (SLE), but their relationship with cardiac disease is less ...
Creso Abreu Falcão   +4 more
doaj   +1 more source

Hepatic venous outflow block in a young patient with Systemic Lupus Erythematosus [PDF]

open access: yesJournal of Analytical Research in Clinical Medicine, 2015
Introduction: Hepatic venous outflow block or Budd-Chiari syndrome is a severe liver disease with a 3 years survival rate of 50%. Several conditions have been implicated as a cause of Budd-Chiari syndrome, including myeloproliferative disorders ...
Ali Ghavidel
doaj   +1 more source

Home - About - Disclaimer - Privacy